semaglutide oral cardiovascular indication 2025 news semaglutide oral cardiovascular indication 2025 news At ADA 2025, the SOUL trial revealed that oral semaglutide ( FDA Clears Semaglutide For Cardiac

"Everything is so dry

A study on Saxenda (liraglutide) showed that people can lose 8% of their starting weight after taking 3mg per day for 68 weeks

The same intervention might have different efficacy across patient profiles

Data on spironolactone are limited, but no meaningful interactions are expected based on metabolic pathways

For instance, 15.8% of people taking a 0.5 mg injection experienced nausea, compared to 20.3% of people taking a 1.0 mg injection in clinical trials

Weight Loss Timeline: First Month to Three Months Measurable weight loss typically emerges between weeks 2 and 4 of consistent GLP-1 therapy, though the first week usually shows minimal scale change despite reduced hunger